Jyoti D. Patel

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon <i>EGFR</i> Mutations

  Molecular Cancer Therapeutics · 2026-05-13

• First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non–Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study

  Clinical Cancer Research · 2026-04-10 · 1 citations

• Table S2 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in &lt;i&gt;RET&lt;/i&gt;-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Table S3 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in &lt;i&gt;RET&lt;/i&gt;-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Supplementary Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in &lt;i&gt;RET&lt;/i&gt;-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in &lt;i&gt;RET&lt;/i&gt;-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Unmet Need and Treatment Expectations of Previously Treated Patients With Epidermal Growth Factor Receptor-Mutated Advanced Nonsmall Cell Lung Cancer: A Qualitative Interview Study

  Clinical Lung Cancer · 2026-02-17

• Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i> -Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  Clinical Cancer Research · 2026-01-15 · 1 citations

• Unmet Need and Treatment Expectations of Previously Treated Patients with Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer: A Qualitative Interview StudyPreprint

  SSRN Electronic Journal · 2026-01-01

• Supplementary Table S5 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• Supplementary Table S3 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• Supplementary Figure S2 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• Supplementary Figure S1 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• Supplementary Table S4 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• Supplementary Table S7 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• Supplementary Table S6 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• Supplementary Table S8 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• Supplementary Table S1 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• Supplementary Table S2 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study

  Journal of Thoracic Oncology · 2025-10-30 · 4 citations